Windlas Biotech Valuation Shifts to Fair Amidst Sector Comparisons

Valuation Metrics and Recent Changes

As of 16 March 2026, Windlas Biotech’s P/E ratio stands at 23.33, a figure that signals a moderate premium compared to its own historical valuation but remains reasonable within the broader sector context. The price-to-book value ratio is 2.91, indicating investors are paying nearly three times the company’s net asset value. These multiples have contributed to the company’s valuation grade being downgraded from attractive to fair on 4 February 2026, reflecting a more cautious stance by analysts and investors alike.

Other valuation indicators include an enterprise value to EBIT (EV/EBIT) of 17.95 and an EV to EBITDA of 12.64, both suggesting that the company is valued at a premium relative to its earnings before interest, taxes, depreciation, and amortisation. The EV to capital employed ratio is 4.36, while EV to sales is 1.53, further underscoring the moderate valuation premium.

The PEG ratio, which adjusts the P/E for earnings growth, is relatively elevated at 3.22, signalling that the stock’s price growth expectations may be outpacing its earnings growth potential. Dividend yield remains modest at 0.78%, consistent with the company’s reinvestment focus in research and development.

Comparative Analysis with Peers

When compared with key peers in the Pharmaceuticals & Biotechnology sector, Windlas Biotech’s valuation appears more moderate. For instance, Ajanta Pharma trades at a P/E of 37.21 and is rated as expensive, while J B Chemicals & Pharmaceuticals is considered very expensive with a P/E of 45.2. Emcure Pharma and Gland Pharma also carry expensive valuations with P/E ratios of 29.96 and 30.94 respectively.

Global pharmaceutical giants such as Pfizer and AstraZeneca Pharma exhibit very expensive valuations, with Pfizer’s P/E at 27.66 and AstraZeneca’s soaring to 100.7, reflecting their dominant market positions and growth prospects. Similarly, Sai Life Sciences and Wockhardt are trading at very high multiples, with Wockhardt’s P/E at an extraordinary 153.66, indicating significant investor optimism or speculative positioning.

Within this context, Windlas Biotech’s fair valuation grade suggests it is more reasonably priced relative to these peers, offering a potentially less risky entry point for investors seeking exposure to the sector without the premium cost of larger or more aggressively valued companies.

Financial Performance and Returns Context

Windlas Biotech’s return profile over various time horizons reveals a mixed picture. The stock has underperformed the Sensex over the short term, with a one-week return of -0.65% compared to the Sensex’s -5.52%, and a one-month return of -8.07% versus the Sensex’s -9.76%. Year-to-date, the stock has declined by 7.1%, while the Sensex has fallen 12.5%, indicating relative resilience.

However, over the one-year period, Windlas Biotech’s stock has declined by 16.59%, contrasting with the Sensex’s positive 1.0% return. This underperformance may reflect sector-specific challenges or company-specific factors impacting investor sentiment. On a longer-term basis, the stock has delivered a robust 196.09% return over three years, significantly outperforming the Sensex’s 28.03% gain, highlighting the company’s growth potential and value creation over time.

Return on capital employed (ROCE) stands at a healthy 24.6%, signalling efficient use of capital to generate profits, while return on equity (ROE) is 12.6%, a moderate figure that suggests steady shareholder returns but room for improvement compared to industry leaders.

Valuation Grade and Market Capitalisation

Windlas Biotech is classified as a small-cap company, which typically entails higher volatility and growth potential compared to large-cap peers. The recent downgrade in its Mojo Grade from Hold to Sell, with a Mojo Score of 34.0, reflects a more cautious outlook from analysts, likely influenced by the shift in valuation from attractive to fair and the company’s relative underperformance over the past year.

Despite this, the company’s valuation remains more palatable than many of its sector peers, which are trading at expensive or very expensive levels. This relative valuation advantage could appeal to investors seeking exposure to the pharmaceuticals and biotechnology sector without the elevated risk associated with high multiples.

Price Movement and Trading Range

Windlas Biotech’s current share price is ₹738.60, unchanged from the previous close. The stock’s 52-week high is ₹1,137.60, while the 52-week low is ₹708.90, indicating a wide trading range and significant volatility over the past year. Today’s intraday range has been between ₹716.60 and ₹738.60, suggesting some buying interest near the lower end of the recent price band.

Given the valuation shift and recent price action, investors may want to monitor the stock’s ability to sustain support levels and assess whether the fair valuation rating translates into a buying opportunity or if further downside risk remains.

Outlook and Investor Considerations

Windlas Biotech’s transition from an attractive to a fair valuation grade signals a more tempered market view, reflecting both the company’s current financial metrics and broader sector dynamics. While the company’s valuation multiples remain reasonable compared to many peers, the downgrade in Mojo Grade to Sell suggests caution.

Investors should weigh the company’s solid three-year returns and efficient capital utilisation against its recent underperformance and elevated PEG ratio. The relatively low dividend yield also indicates that returns are primarily driven by capital appreciation rather than income generation.

In the context of a competitive pharmaceuticals and biotechnology sector, where many peers trade at expensive valuations, Windlas Biotech offers a more moderate valuation profile. However, the company’s small-cap status and recent rating downgrade highlight the importance of careful portfolio allocation and risk management.

Conclusion

Windlas Biotech Ltd’s valuation parameters have shifted notably, with key multiples such as P/E and P/BV moving from attractive to fair levels. This change, coupled with a downgrade in analyst rating to Sell, reflects a more cautious market stance despite the company’s strong longer-term returns and efficient capital use. Compared to its sector peers, Windlas Biotech remains reasonably valued, presenting a potential opportunity for investors seeking exposure to pharmaceuticals and biotechnology at a moderate premium. Nonetheless, the recent price performance and rating changes warrant careful consideration before initiating or increasing positions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today